1. Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice
- Author
-
Kanda, Naoki, Seno, Hiroshi, Kawada, Mayumi, Sawabu, Tateo, Uenoyoma, Yoshito, Nakajima, Toshio, Konda, Yoshitaka, Fukui, Hirokazu, Takeuchi, Toshiyuki, and Chiba, Tsutomu
- Subjects
Gastrin -- Health aspects ,Genetically modified mice -- Physiological aspects ,COX-2 inhibitors -- Dosage and administration ,Biological sciences - Abstract
Gastrin promotes gastric mucosal growth, and hypergastrinemia induces gastric mucosal hypertrophy. Recently, it has been reported that gastrin induces cyclooxygenase-2 (COX-2) in human gastric and colorectal cancer cell lines. However, whether COX-2 is involved in gastrin-induced gastric mucosal growth in vivo is unknown. We investigated the role of COX-2 in gastrin-induced gastric mucosal hypertrophy using gastrin transgenic mice. Hypergastrinemic mice [mice with mutated gastrin under the control of the [beta]-actin promoter (ACT-GAS mice)] received the COX-2 inhibitor celecoxib (0, 200, or 500 mg/kg of diet) from 5 wk of age and were killed at 16 or 24 wk. Some ACT-GAS mice received celecoxib from 16 wk and were killed at 24 wk. Eighty-week-old ACT-GAS mice without celecoxib treatment were also examined. The thickness of the gastric mucosa, cell populations, COX-2 expression, and PG[E.sub.2] levels were evaluated. All ACT-GAS mice showed gastric mucosal hypertrophy, and four of six 80-wk-old ACT-GAS mice developed gastric cancer. COX-2 was expressed in interstitial cells of the hypertrophic gastric mucosa and gastric cancers. Moreover, PGE2 levels in the gastric mucosa of ACT-GAS mice were significantly higher than those of normal mice. With treatment with celecoxib, PG[E.sub.2] levels, the gastric mucosal thickness, and the number of total gastric cells per gastric gland of ACT-GAS mice were significantly decreased. The decrease in gastric mucosal thickness was caused by a reduction of foveolar hyperplasia. The thickness of glandules and the number of Ki67-positive cells were not significantly changed. In conclusion, COX-2 contributes to gastrin-induced mucosal hypertrophy of the stomach. prostaglandin [E.sub.2]; gastric cancer; foveolar hyperplasia
- Published
- 2006